United Therapeutics CEO Executes Pre-Arranged Option Exercise & Sale
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Transaction Report: UNITED THERAPEUTICS Corp (UTHR)
**Filing Date:** 2026-09-30 | **Transaction Date:** 2026-09-29
### Insider Details
- **Insider:** ROTHBLATT MARTINE A
- **Role:** Chairperson & CEO (Director, Officer)
### Transaction Summary
- **Type:** Option Exercise & Sale (Rule 10b5-1 Plan)
- **Shares Sold:** 9,500
- **Average Price:** ~$477.42
- **Total Gross Value:** ~$4,535,480
- **Exercise Price:** $117.76
- **Post-Transaction Holdings:** 324,443 shares (indirect via Trust) + substantial other direct/indirect holdings
- **Significance:** Low (Pre-arranged Rule 10b5-1 trading plan)
Comprehensive Analysis
Transaction Analysis: United Therapeutics Corp (UTHR)
Overview
On September 29, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options at an exercise price of $117.76 per share and concurrently sold the resulting 9,500 shares of common stock at weighted-average prices ranging from $472.05 to $486.77, yielding total gross proceeds of approximately $4.54 million.
Plan Context & Nature of Transaction
- Rule 10b5-1 Plan: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan covers the scheduled exercise and sale of up to 1,734,410 stock options expiring March 15, 2027, continuing until the earlier of total plan completion or December 31, 2026.
- Significance Evaluation: Because this is an exercise of options scheduled to expire in early 2027 and executed via a pre-established 10b5-1 trading plan, it represents routine estate and compensation planning rather than a directional signal on company performance. Rothblatt continues to hold substantial equity in United Therapeutics across direct and family trust accounts.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.